- Home
- SISI vs IMRX Comparison
SISI vs IMRX Comparison
Compare SISI & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- IMRX
- Stock Information
- Founded
- SISI 1997
- IMRX 2008
- Country
- SISI China
- IMRX United States
- Employees
- SISI N/A
- IMRX N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- IMRX Health Care
- Exchange
- SISI Nasdaq
- IMRX Nasdaq
- Market Cap
- SISI 227.4M
- IMRX 232.9M
- IPO Year
- SISI 2016
- IMRX 2021
- Fundamental
- Price
- SISI $5.05
- IMRX $5.51
- Analyst Decision
- SISI
- IMRX Strong Buy
- Analyst Count
- SISI 0
- IMRX 4
- Target Price
- SISI N/A
- IMRX $13.00
- AVG Volume (30 Days)
- SISI 1.6M
- IMRX 970.3K
- Earning Date
- SISI 09-29-2025
- IMRX 08-13-2025
- Dividend Yield
- SISI N/A
- IMRX N/A
- EPS Growth
- SISI N/A
- IMRX N/A
- EPS
- SISI N/A
- IMRX N/A
- Revenue
- SISI $9,601,324.00
- IMRX N/A
- Revenue This Year
- SISI N/A
- IMRX N/A
- Revenue Next Year
- SISI N/A
- IMRX N/A
- P/E Ratio
- SISI N/A
- IMRX N/A
- Revenue Growth
- SISI 1133.26
- IMRX N/A
- 52 Week Low
- SISI $4.71
- IMRX $1.10
- 52 Week High
- SISI $664.80
- IMRX $6.35
- Technical
- Relative Strength Index (RSI)
- SISI 38.19
- IMRX 61.94
- Support Level
- SISI $5.82
- IMRX $5.17
- Resistance Level
- SISI $6.00
- IMRX $6.35
- Average True Range (ATR)
- SISI 0.66
- IMRX 0.60
- MACD
- SISI 0.13
- IMRX 0.08
- Stochastic Oscillator
- SISI 6.10
- IMRX 72.90
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.